The results showed that CISD1 was significantly and positively correlated with StromalScore in LAML and BLCA, suggesting that patients with higher expression of CISD1 may be more resistant to therapies in these cancers; while CISD1 showed significantly negative correlation with StromalScore in UCEC, acute lymphocytic leukemia, LGG, GBMLGG, COAD, THCA, SKCM, KIRC, and KIPAN (Fig. 7A), suggesting that patients with higher CISD1 expression might respond better to certain therapies and have better prognoses in these cancers. This evidence concerns the gene CISD1 and cancer.